Cardiff Oncology, Inc. (NASDAQ:CRDF) Short Interest Update

Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) was the recipient of a large increase in short interest in November. As of November 30th, there was short interest totalling 8,180,000 shares, an increase of 6.0% from the November 15th total of 7,720,000 shares. Based on an average daily volume of 1,480,000 shares, the short-interest ratio is presently 5.5 days.

Insider Activity at Cardiff Oncology

In other Cardiff Oncology news, Director Gary W. Pace bought 350,115 shares of the firm's stock in a transaction dated Wednesday, December 11th. The shares were purchased at an average price of $2.60 per share, for a total transaction of $910,299.00. Following the transaction, the director now directly owns 1,047,876 shares of the company's stock, valued at approximately $2,724,477.60. This represents a 50.18 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 7.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On Cardiff Oncology

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Point72 DIFC Ltd purchased a new position in Cardiff Oncology in the 2nd quarter worth approximately $27,000. Ground Swell Capital LLC purchased a new stake in shares of Cardiff Oncology in the 2nd quarter valued at approximately $38,000. Dimensional Fund Advisors LP increased its holdings in shares of Cardiff Oncology by 34.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 19,098 shares of the company's stock worth $42,000 after buying an additional 4,892 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Cardiff Oncology during the 3rd quarter valued at approximately $64,000. Finally, Invst LLC acquired a new position in Cardiff Oncology in the second quarter valued at approximately $74,000. 16.29% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have issued reports on CRDF. HC Wainwright decreased their price objective on shares of Cardiff Oncology from $14.00 to $13.00 and set a "buy" rating on the stock in a report on Friday, November 8th. Craig Hallum initiated coverage on shares of Cardiff Oncology in a research note on Friday, September 6th. They issued a "buy" rating and a $8.00 price target on the stock. Finally, Piper Sandler boosted their price objective on Cardiff Oncology from $7.00 to $10.00 and gave the stock an "overweight" rating in a research note on Friday.

Cardiff Oncology Trading Up 2.8 %

CRDF stock traded up $0.11 during midday trading on Monday, reaching $4.03. The stock had a trading volume of 1,723,263 shares, compared to its average volume of 1,180,133. Cardiff Oncology has a 52-week low of $1.30 and a 52-week high of $6.42. The company's fifty day simple moving average is $2.92 and its 200 day simple moving average is $2.61. The company has a market cap of $206.05 million, a price-to-earnings ratio of -4.29 and a beta of 1.89.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.